Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease
NCT03493412 · University of Nebraska · PHASE4 · withdrawn · last registry update 2024-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “discontinued due to change in operating plans prior to study initiation and enrollment” | – | Registry record, University of Nebraska |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PAH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-03Results posted on the registry: Providence VA Medical Center, Kuvan (NCT02353312)
- 2025-06-12Results posted on the registry: APR Applied Pharma Research s.a., RLF-OD032 + Kuvan (NCT06481709)
- 2023-12-19Also stopped (withdrawn): University of Massachusetts, Amherst, Tetrahydrobiopterin + Placebo oral tablet (NCT04014712)
- 2023-11-14Results posted on the registry: PTC Therapeutics, PTC923 (NCT03519711)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision